Group 1 - The core viewpoint of the news highlights the positive performance of the Hong Kong Stock Connect Technology ETF (513860), which rose by 1.29% to a price of 0.71 yuan, with a trading volume of 20.75 million yuan as of May 20, 2025 [1] - Notable constituent stocks include 3SBio, which increased by over 29%, and other companies like Innovent Biologics, Zai Lab, and Li Auto, which saw gains of over 4% [1] - On May 19, 2025, 3SBio entered into an exclusive licensing agreement with Pfizer, granting Pfizer global rights to the PD-1/VEGF bispecific antibody (code: SSGJ-707) and commercialization rights in China [1] - CMB International anticipates that the pharmaceutical industry will experience valuation recovery in 2025, driven by factors such as innovative drug exports, optimization of domestic procurement policies, and the implementation of innovative drug insurance catalog [1] Group 2 - The latest scale of the Hong Kong Stock Connect Technology ETF reached 1.89 billion yuan [2] - Over the past 18 trading days, the ETF has attracted a total of 385 million yuan in inflows [2] - The ETF closely tracks the CSI Hong Kong Stock Connect Technology RMB Index, which selects 50 large-cap, high R&D investment, and high revenue growth technology leading companies from the Hong Kong Stock Connect universe [1]
三生制药全球授权，港股通科技ETF(513860)上涨1.29%